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Primary erythermalgia is a rare disorder characterized by recurrent attacks of red, warm and painful hands, and/or
feet. We previously localized the gene for primary erythermalgia to a 7.94 cM region on chromosome 2q. Recent-
ly, Yang et al identiﬁed two missense mutations of the sodium channel a subunit SCN9A in patients with er-
ythermalgia. The presence of voltage-gated sodium channels in sensory neurons is thought to play a crucial role in
several chronic painful neuropathies. We examined four different families and two sporadic cases and detected
missense sequence variants in SCN9A to be present in primary erythermalgia patients. A total of ﬁve of six
mutations were located in highly conserved regions. One family with autosomal dominantly inherited erythermalgia
was double heterozygous for two separate SCN9A mutations. These data establish primary erythermalgia as a
neuropathic disorder and offers hope for treatment of this incapacitating painful disorder.
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Primary erythermalgia is an autosomal dominant condition
that is featured by intermittent attacks of red, warm, swollen
extremities (Drenth and Michiels, 1990). Patients develop
complaints at young age, mostly within the first decade of
life. Typically, attacks are provoked by warmth and exercise,
but in more advanced cases, symptoms can progress to
multiple flares a day. With progression symptoms can ex-
tend to upper arms and legs and even torso and can be
present constantly (Drenth and Michiels, 1994). The pathol-
ogy of primary erythermalgia is unknown although re-
cent studies have suggested that increased microvascular
arteriovenous shunting in deep dermal plexa inducing hy-
poxia is responsible for the pain (Mork et al, 2000). It is not
known however, whether this actually underlies primary er-
ythermalgia or that it arises as a secondary phenomenon.
On the other hand there are indications for an impaired
small fiber function in primary erythermalgia suggesting a
neuropathic component (Orstavik et al, 2004). Treatment of
primary erythermalgia is considered to be very difficult, and
although a great variety of therapeutic options have been
proposed, none of them have brought uniform and sus-
tained relief. Primary erythermalgia can be regarded as a
human model for some types of pain, and as such it can
offer great insight in the pathophysiology of pain (Orstavik
et al, 2003). The familial character of primary erythermalgia
suggests that gene mutations underlie the disease. Identi-
fication of the gene and study of the incriminated protein
can teach us much about the pathophysiology of primary
erythermalgia and also offer us an opening to search for
treatment.
A recent genome-wide linkage study with five kindreds
with erythermalgia placed the gene for primary er-
ythermalgia on chromosome 2q (Drenth et al, 2001). An
analysis of recombinant events in one family identified
marker D2S2370 at the centromeric end and marker
D2S1776 at the telomeric end as flanking markers. Inspec-
tion of the linked interval reveals that there is a cluster of five
sodium channels genes (SCN1a, SCN2a, SCN3a, SCN7a,
SCN9A) located on chromosome 2q. Voltage-sensitive so-
dium channels play a critical role in rapid membrane depo-
larization that is responsible for the rising phase of the
action potential in most excitable cells (Catterall, 2000). The
voltage sensitive sodium channel complex is composed of
a subunits of 260 kDa that forms the voltage sensitive and
ion-selective pore and smaller auxiliary b subunit(s) of 33–36
kDa, that can modulate the kinetics and voltage depend-
ence of channel gating of the a subunits. The voltage-gated
sodium channel subunits encoded by SCN1a, SCN2a,
SCN3a, SCN7a on chromosome 2q are highly related,
share at least 85% of the amino acid sequence for the
transmembrane and extracellular domains, and are all
tetrodoxin sensitive (Chan et al, 2002). Three of the genes
(SCN1a, SCN2a, SCN3a) encode for voltage-gated sodium
channel subunits that are mainly expressed in the central
nervous system but one (SCN9A), encoding for Nav1.7, is
predominantly expressed in the peripheral nervous system
(Klugbauer et al, 1995; Toledo-Aral et al, 1997).
Indeed, on the basis of available linkage data, Chinese
researchers examined a three-generation family with inher-
ited primary erythermalgia and a isolated case and se-
quenced the sodium channel alpha subunit SCN9A in their
patients (Kanadia et al, 2003). These investigators discov-
ered a missense mutation (T2573A) that segregated with
the disease in a family, whereas a T2543C mutation was
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present in their single sporadic case. This suggests that
SCN9A mutations cause primary erythermalgia, although
confirmation is lacking to date.
Therefore, we hypothesized that mutations in SCN9A
might be associated with painful neuropathy as is seen in
primary erythermalgia. To test the hypothesis that SCN9A
mutations cause primary erythermalgia, we sequenced this
gene in patients stemming from four families and two spo-
radic cases.
Results
Mutational analysis We analyzed DNA from familial cases
from a total of four families and two sporadic cases for
SCN9A mutations by automated bidirectional sequencing of
PCR-amplified genomic DNA for each of the 26 SCN9A
exons including the exon–intron junctions. In four familial
cases and a single sporadic case, we identified single-nuc-
leotide substitutions that were spread over the SCN9A
genome, all of which resulted in missense amino acid sub-
stitutions. Table I summarizes the various SCN9A mutations
that were found among our patients. We detected a SCN9A
mutation (T2543C) in a proband from French family (#2)
(Fig 1). This mutation was previously described in a sporadic
Chinese patient (Yang et al, 2004). We detected a novel
C1185A mutation in a Dutch patient from family 3 with very
severe primary erythermalgia. In another French family (#4)
we found a novel T647C mutation in the SCN9A sequence
that was present in the affected father as well as in his
affected daughter. We detected a C2572T mutation in a
proband from a Canadian family (#5) with an especially se-
vere phenotype, and this mutation changes the amino acid
composition from leucine to phenylalanine (L858F). In-
terestingly, another mutation (T2573A) in the same codon
(858) has been described in association with primary er-
ythermalgia in a Chinese family but in this case the mutation
changes leucine for histidine. The proband from this family is
double heterozygous at the same locus for a second mu-
tation C1828A that changes the amino acid sequence at
codon 610 from proline to threonine. We detected a mis-
sense mutation (C3448T) in exon 18 in one of our two spo-
radic primary erythermalgia patients. In the last sporadic
patient, bidirectional genomic sequencing failed to identify
any SCN9A variants. The clinical features of this patient
were comparable with other cases in whom we did detect
mutations. The detected SCN9A sequence variants were not
observed in any of the 100 control chromosomes and, when
tested, segregated with the disease in families. Four muta-
tions (N395K, F216S, I848T, and L858F) are located in the
sodium channel pore region whereas two mutations (P610T
and R1150W) are outside the ion transport region.
Polymorphisms During our studies we detected five non-
coding known SCN9A polymorphisms (A174G, G444A,
T1119C, A1266G, T1287A). These were mostly seen in a
heterozygous state, but we also observed homozygous
T1119C, A1266G, T1287A variants.
Multiple alignment In order to assess the relative impor-
tance of the detected mutations we decided to perform
multiple alignment of nucleotide sequence of SCN9A using
the MULTALIN program. (http://prodes.toulouse.inra.fr/
multalin/multalin.html) Sequences related to SCN9A were
identified by BLAST searches (http://www.ncbi.nlm.nih.gov/
BLAST/). These sequences included HS, Homo sapiens;
CP, Cynops pyrrhogaster; RN, Rattus norvegicus; OC, Or-
yctolagus cuniculus; and MM, Mus musculus. Table II shows
the three nucleotides that encode a codon in the hu-
man mRNA sequence. SCN9A mutations in primary er-
ythermalgia affect nucleotides that are highly conserved
among a wide range of species. This suggest that these
mutations affect structurally and/or mechanistic important
residues in the sequence. The C3448T mutation that was
detected in a sporadic case is a notable exception. The
triplet that encodes codon 1150 is variable and only O.
Table I. Summary of the SCN9A mutations detected in primary
erythermalgia
Family Patient number Exon
Mutation
Nucleotide Amino acid
2 3076 15 T2543C I848T
3 3265 9 C1185A N395K
4 3503 5 T647C F216S
5 3077 11 C1828A P610T
5 3077 15 C2572T L858F
Sporadic 1189 18 C3448T R1150W
Sporadic 1244   
Figure1
Mutations in SCN9A in primary erythermalgia. Cartoon represents
the genomic sequence of SCN9A with and vertical boxes indicate the
coding exons. Seven SCN9A mutations in primary erythermalgia pa-
tients have been discovered so far and are depicted. The asterix rep-
resents the mutation that has been found in another study. (Yang et al,
2004) Sequence electrospherograms showing sequences for each mu-
tation are discovered in this study.
1334 DRENTH ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
cuniculus shares the exact same nucleotides with men. The
fact that the mutation does not affect a highly conserved
nucleotide sequence might suggest that this mutation does
not cause the phenotype but that it is rather an innocent
sequence variation.
Discussion
This report reports the identification of the SCN9A gene as
responsible for primary erythermalgia on the basis of avail-
able positional cloning data. Our results confirm the earlier
report that had detected SCN9A mutations to a single fam-
ily and a sporadic case (Yang et al, 2004). Our conclusion is
based on discovery of six missense mutations, none of
which occurred in 4100 unaffected control chromosomes
among a sample of for primary erythermalgia families and a
sporadic case. All mutations alter the amino acid compo-
sition of the protein and all, but one, occur in highly con-
served regions of the SCN9A sequence. On the other hand,
the results from this study should be interpreted with cau-
tion. It is unsure whether the detected SCN9A sequence
variants actually cause the disease. Although the genetic
data may infer causality, specific functional data are lacking
to date.
SCN9A is part of a cluster of sodium channels genes on
chromosome 2 that probably arose by duplication of a
common ancestral locus. SCN9A encodes the Nav1.7 so-
dium channel which is thought to play a crucial role in the
establishment of the hyperexcitability state of the sensory
neurons that contribute to the abnormal processing of no-
ciceptive and/or tactile information. The presence of volt-
age-gated sodium channels in sensory neurons plays
crucial role in several chronic painful neuropathies (Lai
et al, 2003). For instance, in painful neuromas, a clinical
situation that can arise after trauma to a peripheral nerve,
there is evidence of Nav1.7 accumulation in histological
sections (Kretschmer et al, 2002). Transfection experiments
for two SCN9A mutations (I848T or L858H) associated with
primary erythermalgia indicate that these mutations shifted
the voltage dependence of activation in the hyperpolarizing
direction (Cummins et al, 2004). Deactivation of the Nav1.7
channel was slowed by both mutations and the size of ramp
currents produced by the sodium channels in response to
slow depolarizations was likewise increased. This might
suggest that excitability of sensory neurons that express
the Nav1.7 channel is increased. These findings corroborate
with recent neurophysiological experiments (Davis et al,
2003). In another study with erythermalgia patients, mi-
croneurographic recordings from single C-nociceptive fib-
ers demonstrated reduced conduction velocities and
increased activity-dependent slowing of the conduction ve-
locity of afferent C-nociceptive fibers (Orstavik et al, 2003).
In addition, mechano-insensitive fibers appeared to be
spontaneously active or to be sensitized to mechanical
stimuli. These mechano-insensitive C-nociceptors can con-
tribute to the observed skin vasodilation by the release of
vasoactive neuropeptides. As such, hyperexcitability of C-
nociceptive fibers might be responsible for redness and
warming as well as the pain in erythermalgia. It is possible
that erythermalgia is caused by a gain-of-function of Nav1.7
channel. Nav1.7 channel knockout mice for example, have
increased mechanical and thermal pain thresholds and re-
duced inflammatory pain response which emphasizes the
crucial role of Nav1.7 in mediating pain (Nassar et al, 2004).
The identification of SCN9A mutations in primary er-
ythermalgia represents a paradigm shift in the thinking
about the pathogenesis of the disease. Former hypotheses
were formulated on the basis that maldistribution of blood
flow were the basis of the symptoms (Littleford et al, 1999).
According to this concept, the blood flow over the arterio-
venous shunts is increased, whereas nutritive perfusion is
decreased. The inadequate nutritive blood flow induces su-
perficial hypoxia, leading to an acidic pH and the accumu-
lation of vasodilatory mediators. When these vasodilatory
mediators reach the arteriovenous shunts a vicious circle is
initiated. Increased flow through these thermoregulatory
shunts will further reduce nutritive perfusion and in addition,
increase temperature and worsen the hypoxia because of
increased energy consumption. The discovery of SCN9A
mutations affecting Nav1.7 in these patients lends support
to the concept that primary erythermalgia is a small fiber
neuropathic disorder (Davis et al, 2003).
The pathophysiology of a phenotypically closely related
disorder, erythromelalgia, sharply contrasts with that of pri-
mary erythermalgia. In erythromelalgia, patients likewise
suffer from red and congested extremities with raised skin
temperature and painful burning sensations. The basis for
the disease is caused by the effects of thrombocythemia,
which leads to thrombotic occlusions of arterioles and small
Table II. Multiple alignment of SCN9A sequence among species
Species
Mutation
T647C C1185A T1828A T2543C C2572T C3448T
HS T T C A A C C C A A T T C T C C G G
CP T T C A A C C C A A T T C T C G C A
RN T T C A A C C C A A T T C T C A G G
OC T T C A A C C C A A T T C T C C G G
MM T T C A A C C C A A T T C T C A G G
Mutation T C C A A A A C A A C T T T C T G G
HS, Homo sapiens; CP, Cynops pyrrhogaster; RN, Rattus norvegicus; OC, Oryctolagus cuniculus; MM, Mus musculus. The SCN9A mutations detected
in this study are indicated in bold, and for comparison the corresponding nucleotides for the various species are indicated in grey.
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arteries. This leads to platelet-mediated arteriolar inflam-
mation and fibromuscular intimal proliferation. Aspirin in-
duces normalization of the shortened platelet survival in
thrombocythemia and reverses the inflammatory compo-
nents of erythromelalgia together with an improvement of
the ischemic complications (Michiels et al, 1985). We have
never found evidence for elevated platelet count in our pa-
tients, nor has aspirin provided clinical relief in any of our
patients.
Our findings bring new hopes for the treatment of our
patients. Neuropathic pain in primary erythermalgia is con-
sidered to be very problematic condition in terms of anal-
gesic therapy (Orstavik et al, 2004). In principle, voltage-
gated sodium channels are targets for several drugs, such
as local anesthetics (lidocaine), systemic antiarrhythmics
(mexiletine), and antiepileptic drugs such as phenytoin. In-
deed, in family 3 a single intravenous lidocaine infusion fol-
lowed by oral mexiletine (600 mg daily) rapidly improved the
symptoms (Legroux-Crespel et al, 2003). A similar approach
was successful in patients with erythermalgia (Kuhnert et al,
1999; Jang et al, 2004) which suggest that blocking of the
voltage-gated sodium channels is a valid therapeutic op-
tion. Potentially, Nav1.7 may be a target for a channel-di-
rected analgesic drug, and thus a specific treatment for
primary erythermalgia. Apart from its presence in peripheral
neurons, Nav1.7 is being found in sympathetic neurons, and
pharmacological channel blocking may, in principle, lead to
undesired side effects. On the other hand, targeting Nav1.7
could influence nociceptive more than non-nociceptive
neurons. In any case, our findings open the avenue for a
well-directed search for novel Nav1.7 targeting drugs that
potentially could benefit primary erythermalgia patients.
Material and Methods
Subjects Blood samples for DNA analysis were obtained from
subjects belonging to four families and two sporadic cases with
primary erythermalgia. The study was approved by the institutional
review board at the University Medical Center St Radboud, Ni-
jmegen, the Netherlands and written informed consent was ob-
tained from the subjects. The study was conducted according to
the Declaration of Helsinki Principles. All patients included in this
study had been clinically evaluated by experienced physicians and
the diagnosis was confirmed by the patient’s history and clinical
findings. All patients fulfilled the set of diagnostic criteria for pri-
mary erythermalgia (Drenth and Michiels, 1994). Briefly these cri-
teria were attacks of bilateral or symmetric burning pain in hands or
feet, initiation or aggravation of attacks by standing, exercise, or
exposure to heat, relief by elevation and cold, with attacks when
the affected parts are warm, flushed, and congested (Fig 2) and
lastly the disorder is largely refractory to treatment. Four families
included in this study have been subjects of previous studies (Fig 3)
(Thompson et al, 1979; Martin et al, 1994; Guillet et al, 1995; Leg-
roux-Crespel et al, 2003). Family 2 and 4 stem from France, family
3 comes from the Netherlands. The symptoms of the affected
daughter of family 3 had progressed since the last description
(Drenth et al, 2001) to such a degree that the symptoms were
constantly present and that pain management up to administration
of anesthetics via an epidural catheter was largely ineffective. She
had large ulcers on lower leg and feet, probably as a result of
prolonged cooling, and she developed sepsis and died as a result
at the age of 39 y. Family 5 originates from Canada, whereas family
3 and 4 are three member families each with one affected parent
(family 3 mother, family 4 father) and one affected daughter. The
family history for the two sporadic cases was negative.
DNA sequencing and mutation detection Genomic DNA was
purified from leukocytes from fresh drawn blood or from Epstein–
Barr immortalized cell lines according to established protocols.
Primers were designed with the Oligo 4.0 program (Table III). Mu-
tation screening was carried out for all 26 exons that constitute the
SCN9A open reading frame. Genomic DNA was amplified by PCR
with oligonucleotide primers complementary to flanking intronic
sequences. The 50 mL reaction mixture contained 200 ng of gen-
omic DNA, 10 mM Tris-HCl (pH 9.0), 50 mM KCl, 0.1% TRITON,
2 mM MgCl2, 0.25 mM dNTP, 100 ng of forward and reverse primers,
and 3.0 U Taq-DNA-polymerase. The PCR conditions were 5 min at
951C, then 35 cycles of 30 s at 951C, 30 s at Tm of the used primer
set, and 1 min at 721C, and finally an elongation step at 721C for
5 min. The PCR products were purified after electrophoresis on an
agarose gel with the QIAEXII Gel Extraction Kit (Qiagen, Hilden,
Germany) With the purified amplicons we performed sequencing
using the BigDye terminator kit (Perkin Elmer Applied Biosystems,
Figure2
Red feet in primary erythermalgia. Phenotypical apperance of pri-
mary erythermalgia in the sporadic case with the R1150W mutation.
Note the redness and slightly swollen appearance of feet.
2 3 5
4
Figure3
Pedigree structures of families with primary erythermalgia. Pedi-
gree of four families (2–5) with autosomal dominant inherited primary
erythermalgia. Females and indicated by circles and males by squares.
Blackened figures denote affected individuals, and figures with slashes
denote deceased individuals.
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Boston, Massachusetts) according to the manufacturer’s manual
and the primers used in the PCR reaction. Sequences were analy-
zed on an ABI3700 capillary sequencer (Perkin Elmer Applied Bio-
systems). Sequence electrospherograms were compared with
gene sequence from GenBank and control samples. Further, we
tested sequence variants for segregation among family members,
if available.
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